Noindex: medium evidence

326-61-4

CAS 326-61-4

326-61-4 (CAS 326-61-4) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
326-61-4
CAS Number
326-61-4
UNII
090XZ4C7VN
InChIKey
PFWYHTORQZAGCA-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1366925
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 23438.785714285714 nM 7 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 326-61-4 used for in pharmaceutical contexts?

326-61-4 (CAS 326-61-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 326-61-4?

No adverse-event association or SIDER side-effect rows are rendered for 326-61-4 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 326-61-4 also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for 326-61-4.

What clinical phase is 326-61-4 in?

No phase 1-4 clinical development badge is rendered for 326-61-4 because the matched compound identifier rows do not contain a max-phase value.